Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alzheimer’s Conference Marked By Diversity Of Approaches

Executive Summary

Clinical trial results reported at AAIC demonstrate the variety of approaches, from novel to repurposed, in play as drugmakers attempt to delay the onset, slow the progression or even prevent the world’s second-most dreaded disease. It’s an arena in which first-in-human data can achieve rock star status.

You may also be interested in...



Piramal Imaging Adds New AD Tracers For Leadership In Neuroimaging Research

Piramal is working on what it claims is a well-rounded strategy for an international edge in the field of neuroimaging research. While it is adding newer tracers for detection of the root causes of Alzheimer’s disease, its first approved product Neuraceq is ready to hit the U.S. and European markets later this year.

Cipla Backs Chase For Alzheimer’s Drug Research

The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.

Cipla Backs Chase For Alzheimer’s Drug Research

The top-tier Indian generic company is moving fast into unexpected research territories. In the latest announcement, Cipla said it will partly fund Chase’s Alzheimer’s programs and keep looking for more such opportunities.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel